United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Esperion Therapeutics, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | 12.27% | - | 110.95% | 46.48% | 31.89% | 26.82% |
|---|---|---|---|---|---|---|
| ROA | -18.83% | 7.7% | 12.1% | 9.69% | 9.18% | 9.74% |
| Gross Margin | 100% | 88.5% | 88.27% | 88.13% | 87.83% | 87.87% |
| Net Margin | -15.57% | 7.15% | 10.97% | 8.35% | 7.82% | 8.19% |
| Total Assets | $343,821.00K | $363,238.46K | $384,558.58K | $407,968.51K | $433,673.84K | $459,992.78K |
| Net Income | -$51,745.00K | $27,222.84K | $45,258.93K | $38,405.18K | $38,629.55K | $43,508.71K |